SinoMab BioScience Limited — Share Issue/Capital Change 2022

Nov 3, 2022

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [29 x 44] intentionally omitted <==

==> picture [29 x 44] intentionally omitted <==

SinoMab BioScience Limited 中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the ‘‘Listing Rules’’).

The board (the ‘‘Board’’) of directors (the ‘‘Directors’’) of SinoMab BioScience Limited (the ‘‘Company’’) hereby announces that on 3 November 2022, share options (the ‘‘Share Options’’) were granted by the Company (the ‘‘Grant’’) under its share option scheme adopted at the extraordinary general meeting held on 26 October 2022 (the ‘‘2022 Share Option Scheme’’) to eligible persons (the ‘‘Grantees’’), all of whom are employees of the Company, to subscribe for an aggregate of 25,156,000 new shares of the Company (the ‘‘Shares’’), subject to acceptance of the Grantees. Details of the Grant are set out below:

Date of Grant 3 November 2022 Categories of Grantees Employees Exercise price of HK$1.79 per Share Share Options granted Number of Share 25,156,000 Options granted Closing price of the Shares HK$1.75 per Share on the date of Grant

Average closing price of the HK$1.79 per Share Shares for the five consecutive trading days prior to the date of Grant

– 1 –

Validity period of The Share Options are exercisable for a period of 10 the Share Options years commencing from 3 November 2022 to 2 November 2032

Vesting Schedule of 100% vested on 4 November 2023, being the date of 12 Share Options months after the Date of Grant

Grantees

None of the Grantees is a Director, chief executive or substantial shareholder of the Company, nor an associate (as defined under the Rule 14A.06 of the Listing Rules) of any of them.

Performance Target

No performance target is stipulated.

The remuneration committee of the Company is of the view that the Grant forms part of the management agreement between the Company and the Grantees for the purpose of attracting and retaining the Grantee. This aligns with the purpose of the 2022 Share Option Scheme.

Clawback Mechanism No clawback mechanism is stipulated.

The remuneration committee of the Company is of the view that clawback mechanism is not necessary as the scheme rules of the 2022 Share Option Scheme already provided for the lapse and cancellation of options in different scenarios and provided enough protection to the Company’s interests.

Number of Shares	25,156,020
available for future
grant under scheme
mandate
Number of Shares	10,062,404
available for future
grant under service
provider sublimit (Note)

Note: Service provider sublimit is within the scheme mandate.

By Order of the Board SinoMab BioScience Limited Dr. Shui On LEUNG Executive Director, Chairman and Chief Executive Officer

Hong Kong, 3 November 2022

– 2 –

As at the date of this announcement, the executive director of the Company is Dr. Shui On LEUNG, the non-executive directors of the Company are Dr. Haigang CHEN, Mr. Xun DONG, Ms. Wenyi LIU, Ms. Jie LIU and Mr. Lei SHI, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.

– 3 –